moxifloxacin has been researched along with oritavancin in 5 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (oritavancin) | Trials (oritavancin) | Recent Studies (post-2010) (oritavancin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 245 | 11 | 137 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR | 1 |
| Darpo, B; Lee, SK; Mason, JW; Moon, TE; Sills, N | 1 |
1 trial(s) available for moxifloxacin and oritavancin
| Article | Year |
|---|---|
Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Glycopeptides; Humans; Lipoglycopeptides; Male; Middle Aged; Moxifloxacin; Quinolines; Young Adult | 2010 |
4 other study(ies) available for moxifloxacin and oritavancin
| Article | Year |
|---|---|
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine | 2009 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Lymphoma, Large B-Cell, Diffuse; Macrophages; Mice; Microbial Sensitivity Tests; Microscopy, Electron; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Tumor Cells, Cultured | 2003 |
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Synergism; Fluoroquinolones; Gentamicins; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Polysorbates; Quinolines; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Surface-Active Agents; Vancomycin Resistance | 2008 |